Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine
The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Re...
Saved in:
Published in | mBio Vol. 13; no. 1; p. e0337921 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
22.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study.
The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only. |
---|---|
AbstractList | The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only. The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. IMPORTANCE The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only. ABSTRACT The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. IMPORTANCE The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only. The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Here, we generated a single-dose, fast-acting vesicular stomatitis virus (VSV)-based vaccine derived from the licensed Ebola virus (EBOV) vaccine rVSV-ZEBOV, expressing the SARS-CoV-2 spike protein and the EBOV glycoprotein (VSV-SARS2-EBOV). Rhesus macaques vaccinated intramuscularly (i.m.) with a single dose of VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, intranasal (i.n.) vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to results for control animals. While both i.m. and i.n. vaccination induced neutralizing antibody titers, only i.m. vaccination resulted in a significant cellular immune response. RNA sequencing data bolstered these results by revealing robust activation of the innate and adaptive immune transcriptional signatures in the lungs of i.m. vaccinated animals only. Overall, the data demonstrate that VSV-SARS2-EBOV is a potent single-dose COVID-19 vaccine candidate that offers rapid protection based on the protective efficacy observed in our study. IMPORTANCE The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease. Here, we demonstrate the protective efficacy of a VSV-EBOV-based COVID-19 vaccine against challenge in nonhuman primates (NHPs). When a single dose of the VSV-SARS2-EBOV vaccine was administered intramuscularly (i.m.), the NHPs were protected from COVID-19 within 10 days. In contrast, if the vaccine was administered intranasally, there was no benefit from the vaccine and the NHPs developed pneumonia. The i.m. vaccinated NHPs quickly developed antigen-specific IgG, including neutralizing antibodies. Transcriptional analysis highlighted the development of protective innate and adaptive immune responses in the i.m. vaccination group only. |
Author | Lovaglio, Jamie Clancy, Chad S Feldmann, Friederike Jankeel, Allen O'Donnell, Kyle L Hanley, Patrick W Okumura, Atsushi Thomas, Tina Messaoudi, Ilhem Gourdine, Tylisha Pinski, Amanda N Shifflett, Kyle Furuyama, Wakako Marzi, Andrea Griffin, Amanda J |
Author_xml | – sequence: 1 givenname: Wakako surname: Furuyama fullname: Furuyama, Wakako organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 2 givenname: Kyle surname: Shifflett fullname: Shifflett, Kyle organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 3 givenname: Amanda N surname: Pinski fullname: Pinski, Amanda N organization: Department of Molecular Biology and Biochemistry, University of California-Irvinegrid.266093.8, Irvine, California, USA – sequence: 4 givenname: Amanda J surname: Griffin fullname: Griffin, Amanda J organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 5 givenname: Friederike surname: Feldmann fullname: Feldmann, Friederike organization: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA – sequence: 6 givenname: Atsushi orcidid: 0000-0002-7779-3059 surname: Okumura fullname: Okumura, Atsushi organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 7 givenname: Tylisha surname: Gourdine fullname: Gourdine, Tylisha organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 8 givenname: Allen surname: Jankeel fullname: Jankeel, Allen organization: Department of Molecular Biology and Biochemistry, University of California-Irvinegrid.266093.8, Irvine, California, USA – sequence: 9 givenname: Jamie surname: Lovaglio fullname: Lovaglio, Jamie organization: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA – sequence: 10 givenname: Patrick W surname: Hanley fullname: Hanley, Patrick W organization: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA – sequence: 11 givenname: Tina surname: Thomas fullname: Thomas, Tina organization: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA – sequence: 12 givenname: Chad S surname: Clancy fullname: Clancy, Chad S organization: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA – sequence: 13 givenname: Ilhem orcidid: 0000-0003-3203-2405 surname: Messaoudi fullname: Messaoudi, Ilhem organization: Department of Molecular Biology and Biochemistry, University of California-Irvinegrid.266093.8, Irvine, California, USA – sequence: 14 givenname: Kyle L surname: O'Donnell fullname: O'Donnell, Kyle L organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 15 givenname: Andrea orcidid: 0000-0003-0186-9587 surname: Marzi fullname: Marzi, Andrea organization: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35012339$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1v1DAQhiNUREvpkSvyESGl2LHjOBckuuUjUmERhb1aE8fZ9Sqxt7YD6v_hh-LdlKo94ItH77zzjGY0z7Mj66zOspcEnxNSiLdfLprlOaa0qvOCPMlOClLivCoJOXoQH2dnIWxxepQSQfGz7JiWmBSU1ifZn--wMx365l3UKhpnUe_diBbLVXOZkxoZi746u5lGsMlkRog6oBUoZWwKO9TY6GGcgpoG8MMtaqeYCuKsWwgwJPG3iRsE6NrY9aDRpQsauT4JKx3MoRBdR5fQJpoEN34K-QWERJ8b6RfZ0x6GoM_u_tPs58cPPxaf86vlp2bx_ioHRmuWUw41JaqrtNAVV0xQVlCtFeYYC9qLTpRcKQwqBYqwmquuJFUJZVkJUab1nGbNzO0cbOVuP66_lQ6MPAjOryX4aNSgZUtYSTvOOG8r1lOeGrctUUpRLrDGkFjvZtZuakfdKb1fyPAI-jhjzUau3S8pKlYzQhLg9R3Au5tJhyhHE5QeBrDaTUEWnIiaMFbVyZrPVuVdCF73920IlvtDkWNrnDwciiz26DezH8JYyK2bvE1r_a_51cNB7tH_boj-BSZGyXs |
CitedBy_id | crossref_primary_10_1016_j_ebiom_2022_104203 crossref_primary_10_3389_fimmu_2022_1025500 crossref_primary_10_1016_j_mser_2023_100715 crossref_primary_10_2222_jsv_72_139 crossref_primary_10_1016_j_virol_2023_05_013 crossref_primary_10_2222_jsv_72_7 crossref_primary_10_3390_vaccines10030435 crossref_primary_10_1021_acsinfecdis_1c00600 crossref_primary_10_1038_s41577_023_00972_9 crossref_primary_10_1126_sciadv_adj1428 crossref_primary_10_1128_jvi_01337_22 crossref_primary_10_3390_vaccines12030322 crossref_primary_10_1016_j_ebiom_2023_104463 crossref_primary_10_1080_22221751_2022_2119169 |
Cites_doi | 10.1080/22221751.2020.1747363 10.1038/s41577-018-0005-7 10.4049/jimmunol.1800659 10.1038/s41598-018-29401-x 10.1016/S1473-3099(18)30165-8 10.1126/science.abc6284 10.1371/journal.pntd.0003736 10.1128/JVI.00794-11 10.1093/infdis/jir379 10.3201/eid2506.181620 10.1128/mBio.01503-21 10.3201/eid2606.200516 10.1371/journal.pone.0022200 10.1126/science.aab3920 10.4049/jimmunol.173.10.6357 10.1016/j.intimp.2020.107233 10.1038/s41564-020-0688-y 10.1371/journal.pone.0005547 10.1038/s41598-018-31510-6 10.1111/bph.15143 10.7326/M20-2003 10.1038/nri3156 10.1038/s41586-020-2324-7 10.1016/S2468-1253(20)30126-6 10.1016/j.xcrm.2021.100230 10.1073/pnas.0600397103 10.1016/j.chom.2020.07.018 10.1038/s41586-020-2012-7 10.1073/pnas.1209591110 10.1056/NEJMoa2001316 10.1038/s41586-020-2607-z 10.1038/nri1777 10.1016/j.chom.2020.06.021 10.1016/j.bbrc.2004.03.030 10.1056/NEJMoa2002032 10.1186/s12859-016-1241-0 10.1016/S0140-6736(16)32621-6 10.1038/s41586-020-2608-y 10.1038/s41541-019-0155-z 10.1016/j.cell.2020.08.026 10.1056/NEJMoa2024671 10.1016/j.ebiom.2019.09.055 10.3389/fimmu.2017.01372 10.4172/2157-2526.S1-004 10.1126/sciadv.abj3627 10.1038/s41586-020-2787-6 10.1001/jama.2020.10374 10.1038/s41586-020-2008-3 10.1056/NEJMoa2001191 10.1080/21645515.2019.1649532 10.1038/s41590-020-0782-6 10.1016/S0140-6736(20)30566-3 10.1038/s41586-020-2380-z 10.1101/2021.09.03.458735 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1128/MBIO.03379-21 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2150-7511 |
Editor | Moscona, Anne |
Editor_xml | – sequence: 1 givenname: Anne surname: Moscona fullname: Moscona, Anne |
EndPage | e0337921 |
ExternalDocumentID | oai_doaj_org_article_b1453d6466b74f36931bb1ccc3680e0a 10_1128_mbio_03379_21 03379-21 35012339 |
Genre | Journal Article Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001414 – fundername: Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) grantid: IMVU funderid: https://doi.org/10.13039/100006492 – fundername: HHS | NIH | National Center for Research Resources (NCRR) grantid: UL1 TR001414 funderid: https://doi.org/10.13039/100000097 – fundername: ; grantid: IMVU – fundername: ; grantid: UL1 TR001414 |
GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAUOK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CGR CUY CVF DIK E3Z EBS ECM EIF FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 M~E NPM O5R O5S O9- OK1 P2P PGMZT RHF RHI RNS RPM RSF - 0R ADACO BXI HZ AAYXX CITATION 7X8 5PM AFPKN |
ID | FETCH-LOGICAL-a4394-36a931cd7e8e76c483423eec060083f8d856cc0acd85c1496cd5175a557885003 |
IEDL.DBID | RPM |
ISSN | 2150-7511 |
IngestDate | Tue Oct 22 15:13:34 EDT 2024 Tue Sep 17 21:08:44 EDT 2024 Fri Oct 25 08:50:55 EDT 2024 Fri Dec 06 02:01:01 EST 2024 Tue Feb 22 21:30:05 EST 2022 Sat Nov 02 12:28:25 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | VSV i.n i.m SARS-CoV-2 rhesus macaques vesicular stomatitis virus |
Language | English |
License | This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a4394-36a931cd7e8e76c483423eec060083f8d856cc0acd85c1496cd5175a557885003 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
ORCID | 0000-0002-7779-3059 0000-0003-0186-9587 0000-0003-3203-2405 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749411/ |
PMID | 35012339 |
PQID | 2618914479 |
PQPubID | 23479 |
PageCount | 19 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b1453d6466b74f36931bb1ccc3680e0a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8749411 proquest_miscellaneous_2618914479 crossref_primary_10_1128_mbio_03379_21 asm2_journals_10_1128_mbio_03379_21 pubmed_primary_35012339 |
PublicationCentury | 2000 |
PublicationDate | 2022-02-22 |
PublicationDateYYYYMMDD | 2022-02-22 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-22 day: 22 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | mBio |
PublicationTitleAbbrev | mBio |
PublicationTitleAlternate | mBio |
PublicationYear | 2022 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | 33501447 - bioRxiv. 2021 Jan 19:2021.01.19.426885. doi: 10.1101/2021.01.19.426885 Zhou, P, Yang, XL, Wang, XG, Hu, B, Zhang, L, Zhang, W, Si, HR, Zhu, Y, Li, B, Huang, CL, Chen, HD, Chen, J, Luo, Y, Guo, H, Jiang, RD, Liu, MQ, Chen, Y, Shen, XR, Wang, X, Zheng, XS, Zhao, K, Chen, QJ, Deng, F, Liu, LL, Yan, B, Zhan, FX, Wang, YY, Xiao, GF, Shi, ZL (B1) 2020; 579 B26 Huttner, A, Agnandji, ST, Combescure, C, Fernandes, JF, Bache, EB, Kabwende, L, Ndungu, FM, Brosnahan, J, Monath, TP, Lemaître, B, Grillet, S, Botto, M, Engler, O, Portmann, J, Siegrist, D, Bejon, P, Silvera, P, Kremsner, P, Siegrist, C-A, Krishna, S, Addo, MM, Becker, S, Krähling, V, Njuguna, P, Kieny, M-P, Ahmed, R, Anderson, J, Auderset, F, Borgianni, L, Ciabattini, A, Haks, MC, Harandi, A, Heppner, DG, Gerlini, A, Medaglini, D, Ottenhoff, THM, Pejoski, D, Page, M, Pozzi, G, Santoro, F, Dubey, S, Fernandes, JF, Nakaya, H, Orourke, F, Pozzi, G, Rothenberger, S (B53) 2018; 18 Wichmann, D, Sperhake, JP, Lutgehetmann, M, Steurer, S, Edler, C, Heinemann, A, Heinrich, F, Mushumba, H, Kniep, I, Schroder, AS, Burdelski, C, de Heer, G, Nierhaus, A, Frings, D, Pfefferle, S, Becker, H, Bredereke-Wiedling, H, de Weerth, A, Paschen, HR, Sheikhzadeh-Eggers, S, Stang, A, Schmiedel, S, Bokemeyer, C, Addo, MM, Aepfelbacher, M, Puschel, K, Kluge, S (B5) 2020; 173 Furuyama, W, Reynolds, P, Haddock, E, Meade-White, K, Quynh Le, M, Kawaoka, Y, Feldmann, H, Marzi, A (B22) 2020; 5 Case, JB, Rothlauf, PW, Chen, RE, Liu, Z, Zhao, H, Kim, AS, Bloyet, LM, Zeng, Q, Tahan, S, Droit, L, Ilagan, MXG, Tartell, MA, Amarasinghe, G, Henderson, JP, Miersch, S, Ustav, M, Sidhu, S, Virgin, HW, Wang, D, Ding, S, Corti, D, Theel, ES, Fremont, DH, Diamond, MS, Whelan, SPJ (B27) 2020; 28 Wu, F, Zhao, S, Yu, B, Chen, YM, Wang, W, Song, ZG, Hu, Y, Tao, ZW, Tian, JH, Pei, YY, Yuan, ML, Zhang, YL, Dai, FH, Liu, Y, Wang, QM, Zheng, JJ, Xu, L, Holmes, EC, Zhang, YZ (B7) 2020; 579 Mao, R, Qiu, Y, He, JS, Tan, JY, Li, XH, Liang, J, Shen, J, Zhu, LR, Chen, Y, Iacucci, M, Ng, SC, Ghosh, S, Chen, MH (B4) 2020; 5 Wang, J, Thorson, L, Stokes, RW, Santosuosso, M, Huygen, K, Zganiacz, A, Hitt, M, Xing, Z (B40) 2004; 173 Henao-Restrepo, AM, Camacho, A, Longini, IM, Watson, CH, Edmunds, WJ, Egger, M, Carroll, MW, Dean, NE, Diatta, I, Doumbia, M, Draguez, B, Duraffour, S, Enwere, G, Grais, R, Gunther, S, Gsell, PS, Hossmann, S, Watle, SV, Konde, MK, Keita, S, Kone, S, Kuisma, E, Levine, MM, Mandal, S, Mauget, T, Norheim, G, Riveros, X, Soumah, A, Trelle, S, Vicari, AS, Rottingen, JA, Kieny, MP (B24) 2017; 389 Qiu, X, Fernando, L, Alimonti, JB, Melito, PL, Feldmann, F, Dick, D, Stroher, U, Feldmann, H, Jones, SM (B25) 2009; 4 Marzi, A, Engelmann, F, Feldmann, F, Haberthur, K, Shupert, WL, Brining, D, Scott, DP, Geisbert, TW, Kawaoka, Y, Katze, MG, Feldmann, H, Messaoudi, I (B30) 2013; 110 Case, JB, Rothlauf, PW, Chen, RE, Kafai, NM, Fox, JM, Smith, BK, Shrihari, S, McCune, BT, Harvey, IB, Keeler, SP, Bloyet, LM, Zhao, H, Ma, M, Adams, LJ, Winkler, ES, Holtzman, MJ, Fremont, DH, Whelan, SPJ, Diamond, MS (B51) 2020; 28 Holshue, ML, DeBolt, C, Lindquist, S, Lofy, KH, Wiesman, J, Bruce, H, Spitters, C, Ericson, K, Wilkerson, S, Tural, A, Diaz, G, Cohn, A, Fox, L, Patel, A, Gerber, SI, Kim, L, Tong, S, Lu, X, Lindstrom, S, Pallansch, MA, Weldon, WC, Biggs, HM, Uyeki, TM, Pillai, SK (B8) 2020; 382 Wong, JJ, Pung, YF, Sze, NS, Chin, KC (B45) 2006; 103 Neutra, MR, Kozlowski, PA (B41) 2006; 6 B32 B33 Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z, Xiang, J, Wang, Y, Song, B, Gu, X, Guan, L, Wei, Y, Li, H, Wu, X, Xu, J, Tu, S, Zhang, Y, Chen, H, Cao, B (B6) 2020; 395 Munster, VJ, Feldmann, F, Williamson, BN, van Doremalen, N, Perez-Perez, L, Schulz, J, Meade-White, K, Okumura, A, Callison, J, Brumbaugh, B, Avanzato, VA, Rosenke, R, Hanley, PW, Saturday, G, Scott, D, Fischer, ER, de Wit, E (B29) 2020; 585 Li, Q, Guan, X, Wu, P, Wang, X, Zhou, L, Tong, Y, Ren, R, Leung, KSM, Lau, EHY, Wong, JY, Xing, X, Xiang, N, Wu, Y, Li, C, Chen, Q, Li, D, Liu, T, Zhao, J, Liu, M, Tu, W, Chen, C, Jin, L, Yang, R, Wang, Q, Zhou, S, Wang, R, Liu, H, Luo, Y, Liu, Y, Shao, G, Li, H, Tao, Z, Yang, Y, Deng, Z, Liu, B, Ma, Z, Zhang, Y, Shi, G, Lam, TTY, Wu, JT, Gao, GF, Cowling, BJ, Yang, B, Leung, GM, Feng, Z (B9) 2020; 382 Harcourt, J, Tamin, A, Lu, X, Kamili, S, Sakthivel, SK, Murray, J, Queen, K, Tao, Y, Paden, CR, Zhang, J, Li, Y, Uehara, A, Wang, H, Goldsmith, C, Bullock, HA, Wang, L, Whitaker, B, Lynch, B, Gautam, R, Schindewolf, C, Lokugamage, KG, Scharton, D, Plante, JA, Mirchandani, D, Widen, SG, Narayanan, K, Makino, S, Ksiazek, TG, Plante, KS, Weaver, SC, Lindstrom, S, Tong, S, Menachery, VD, Thornburg, NJ (B57) 2020; 26 Guan, WJ, Ni, ZY, Hu, Y, Liang, WH, Ou, CQ, He, JX, Liu, L, Shan, H, Lei, CL, Hui, DSC, Du, B, Li, LJ, Zeng, G, Yuen, KY, Chen, RC, Tang, CL, Wang, T, Chen, PY, Xiang, J, Li, SY, Wang, JL, Liang, ZJ, Peng, YX, Wei, L, Liu, Y, Hu, YH, Peng, P, Wang, JM, Liu, JY, Chen, Z, Li, G, Zheng, ZJ, Qiu, SQ, Luo, J, Ye, CJ, Zhu, SY, Zhong, NS (B2) 2020; 382 Mercado, NB, Zahn, R, Wegmann, F, Loos, C, Chandrashekar, A, Yu, J, Liu, J, Peter, L, McMahan, K, Tostanoski, LH, He, X, Martinez, DR, Rutten, L, Bos, R, van Manen, D, Vellinga, J, Custers, J, Langedijk, JP, Kwaks, T, Bakkers, MJG, Zuijdgeest, D, Rosendahl Huber, SK, Atyeo, C, Fischinger, S, Burke, JS, Feldman, J, Hauser, BM, Caradonna, TM, Bondzie, EA, Dagotto, G, Gebre, MS, Hoffman, E, Jacob-Dolan, C, Kirilova, M, Li, Z, Lin, Z, Mahrokhian, SH, Maxfield, LF, Nampanya, F, Nityanandam, R, Nkolola, JP, Patel, S, Ventura, JD, Verrington, K, Wan, H, Pessaint, L, Van Ry, A, Blade, K, Strasbaugh, A, Cabus, M (B15) 2020; 586 Abrahamsen, G, Sundvold-Gjerstad, V, Habtamu, M, Bogen, B, Spurkland, A (B48) 2018; 8 Tsuda, Y, Safronetz, D, Brown, K, LaCasse, R, Marzi, A, Ebihara, H, Feldmann, H (B58) 2011; 204 Letko, M, Marzi, A, Munster, V (B10) 2020; 5 Hassan, AO, Kafai, NM, Dmitriev, IP, Fox, JM, Smith, BK, Harvey, IB, Chen, RE, Winkler, ES, Wessel, AW, Case, JB, Kashentseva, E, McCune, BT, Bailey, AL, Zhao, H, VanBlargan, LA, Dai, YN, Ma, M, Adams, LJ, Shrihari, S, Danis, JE, Gralinski, LE, Hou, YJ, Schafer, A, Kim, AS, Keeler, SP, Weiskopf, D, Baric, RS, Holtzman, MJ, Fremont, DH, Curiel, DT, Diamond, MS (B12) 2020; 183 Hasenkrug, KJ, Feldmann, F, Myers, L, Santiago, ML, Guo, K, Barrett, BS, Mickens, KL, Carmody, A, Okumura, A, Rao, D, Collins, MM, Messer, RJ, Lovaglio, J, Shaia, C, Rosenke, R, van Doremalen, N, Clancy, C, Saturday, G, Hanley, P, Smith, BJ, Meade-White, K, Shupert, WL, Hawman, DW, Feldmann, H (B36) 2021; 12 Xiong, Y, Liu, Y, Cao, L, Wang, D, Guo, M, Jiang, A, Guo, D, Hu, W, Yang, J, Tang, Z, Wu, H, Lin, Y, Zhang, M, Zhang, Q, Shi, M, Liu, Y, Zhou, Y, Lan, K, Chen, Y (B50) 2020; 9 van Doremalen, N, Lambe, T, Spencer, A, Belij-Rammerstorfer, S, Purushotham, JN, Port, JR, Avanzato, VA, Bushmaker, T, Flaxman, A, Ulaszewska, M, Feldmann, F, Allen, ER, Sharpe, H, Schulz, J, Holbrook, M, Okumura, A, Meade-White, K, Perez-Perez, L, Edwards, NJ, Wright, D, Bissett, C, Gilbride, C, Williamson, BN, Rosenke, R, Long, D, Ishwarbhai, A, Kailath, R, Rose, L, Morris, S, Powers, C, Lovaglio, J, Hanley, PW, Scott, D, Saturday, G, de Wit, E, Gilbert, SC, Munster, VJ (B13) 2020; 586 Cavalcante-Silva, LHA, Carvalho, DCM, Lima, EA, Galvao, J, da Silva, JSF, Sales-Neto, JM, Rodrigues-Mascarenhas, S (B42) 2021; 90 Brining, DL, Mattoon, JS, Kercher, L, LaCasse, RA, Safronetz, D, Feldmann, H, Parnell, MJ (B59) 2010; 60 Estes, JD, Wong, SW, Brenchley, JM (B34) 2018; 18 Munoz-Fontela, C, Dowling, WE, Funnell, SGP, Gsell, PS, Riveros-Balta, AX, Albrecht, RA, Andersen, H, Baric, RS, Carroll, MW, Cavaleri, M, Qin, C, Crozier, I, Dallmeier, K, de Waal, L, de Wit, E, Delang, L, Dohm, E, Duprex, WP, Falzarano, D, Finch, CL, Frieman, MB, Graham, BS, Gralinski, LE, Guilfoyle, K, Haagmans, BL, Hamilton, GA, Hartman, AL, Herfst, S, Kaptein, SJF, Klimstra, WB, Knezevic, I, Krause, PR, Kuhn, JH, Le Grand, R, Lewis, MG, Liu, WC, Maisonnasse, P, McElroy, AK, Munster, V, Oreshkova, N, Rasmussen, AL, Rocha-Pereira, J, Rockx, B, Rodriguez, E, Rogers, TF, Salguero, FJ, Schotsaert, M, Stittelaar, KJ, Thibaut, HJ, Tseng, CT (B38) 2020; 586 Matsumura, T, Semba, K, Azuma, S, Ikawa, S, Gohda, J, Akiyama, T, Inoue, J (B44) 2004; 317 Woo, JS, Srikanth, S, Kim, KD, Elsaesser, H, Lu, J, Pellegrini, M, Brooks, DG, Sun, Z, Gwack, Y (B49) 2018; 201 Marzi, A, Reynolds, P, Mercado-Hernandez, R, Callison, J, Feldmann, F, Rosenke, R, Thomas, T, Scott, DP, Hanley, PW, Haddock, E, Feldmann, H (B52) 2019; 49 Yu, J, Tostanoski, LH, Peter, L, Mercado, NB, McMahan, K, Mahrokhian, SH, Nkolola, JP, Liu, J, Li, Z, Chandrashekar, A, Martinez, DR, Loos, C, Atyeo, C, Fischinger, S, Burke, JS, Slein, MD, Chen, Y, Zuiani, A, Lelis, FJN, Travers, M, Habibi, S, Pessaint, L, Van Ry, A, Blade, K, Brown, R, Cook, A, Finneyfrock, B, Dodson, A, Teow, E, Velasco, J, Zahn, R, Wegmann, F, Bondzie, EA, Dagotto, G, Gebre, MS, He, X, Jacob-Dolan, C, Kirilova, M, Kordana, N, Lin, Z, Maxfield, LF, Nampanya, F, Nityanandam, R, Ventura, JD, Wan, H, Cai, Y, Chen, B, Schmidt, AG, Wesemann, DR, Baric, RS (B14) 2020; 369 Fathi, A, Dahlke, C, Addo, MM (B20) 2019; 15 Menicucci, AR, Versteeg, K, Woolsey, C, Mire, CE, Geisbert, JB, Cross, RW, Agans, KN, Jankeel, A, Geisbert, TW, Messaoudi, I (B31) 2017; 8 Marzi, A, Feldmann, H, Geisbert, TW, Falzarano, D (B17) 2011; S1 Cheung, EW, Zachariah, P, Gorelik, M, Boneparth, A, Kernie, SG, Orange, JS, Milner, JD (B3) 2020; 324 Munster, VJ, Flagg, M, Singh, M, Yinda, CK, Williamson, BN, Feldmann, F, Perez-Perez, L, Schulz, J, Brumbaugh, B, Holbrook, MG, Adney, DR, Okumura, A, Hanley, PW, Smith, BJ, Lovaglio, J, Anzick, SL, Martens, C, van Doremalen, N, Saturday, G, de Wit, E (B35) 2021; 7 Ju, B, Zhang, Q, Ge, J, Wang, R, Sun, J, Ge, X, Yu, J, Shan, S, Zhou, B, Song, S, Tang, X, Yu, J, Lan, J, Yuan, J, Wang, H, Zhao, J, Zhang, S, Wang, Y, Shi, X, Liu, L, Zhao, J, Wang, X, Zhang, Z, Zhang, L (B11) 2020; 584 Mire, CE, Geisbert, JB, Agans, KN, Versteeg, KM, Deer, DJ, Satterfield, BA, Fenton, KA, Geisbert, TW (B18) 2019; 25 Cleary, SJ, Pitchford, S e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 Brining DL (e_1_3_2_60_2) 2010; 60 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_56_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_61_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_59_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_55_2 e_1_3_2_2_2 |
References_xml | – volume: 9 start-page: 761 year: 2020 end-page: 770 ident: B50 article-title: Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1747363 contributor: fullname: Chen, Y – volume: 18 start-page: 390 year: 2018 end-page: 404 ident: B34 article-title: Nonhuman primate models of human viral infections publication-title: Nat Rev Immunol doi: 10.1038/s41577-018-0005-7 contributor: fullname: Brenchley, JM – volume: 201 start-page: 1174 year: 2018 end-page: 1185 ident: B49 article-title: CRACR2A-mediated TCR signaling promotes local effector Th1 and Th17 responses publication-title: J Immunol doi: 10.4049/jimmunol.1800659 contributor: fullname: Gwack, Y – volume: 8 start-page: 11043 year: 2018 ident: B28 article-title: A VSV-based Zika virus vaccine protects mice from lethal challenge publication-title: Sci Rep doi: 10.1038/s41598-018-29401-x contributor: fullname: Marzi, A – volume: 18 start-page: 738 year: 2018 end-page: 748 ident: B53 article-title: Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30165-8 contributor: fullname: Rothenberger, S – volume: 369 start-page: 806 year: 2020 end-page: 811 ident: B14 article-title: DNA vaccine protection against SARS-CoV-2 in rhesus macaques publication-title: Science doi: 10.1126/science.abc6284 contributor: fullname: Baric, RS – volume: 9 year: 2015 ident: B19 article-title: A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0003736 contributor: fullname: Feldmann, H – volume: 85 start-page: 12781 year: 2011 end-page: 12791 ident: B23 article-title: Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus publication-title: J Virol doi: 10.1128/JVI.00794-11 contributor: fullname: Feldmann, H – volume: 204 start-page: S1090 year: 2011 end-page: S1097 ident: B58 article-title: Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection publication-title: J Infect Dis doi: 10.1093/infdis/jir379 contributor: fullname: Feldmann, H – volume: 25 start-page: 1144 year: 2019 end-page: 1152 ident: B18 article-title: Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal Nipah virus disease publication-title: Emerg Infect Dis doi: 10.3201/eid2506.181620 contributor: fullname: Geisbert, TW – ident: B26 article-title: O'Donnell KL , Griffin AJ , Shifflett K , Gourdine T , Thomas T , Long CM , Furuyama W , Marzi A . 2021 . Optimization of single dose VSV-based COVID-19 vaccination in hamsters . BioRxiv doi: 10.1101/2021.09.03.458735 . – volume: 12 year: 2021 ident: B36 article-title: Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques publication-title: mBio doi: 10.1128/mBio.01503-21 contributor: fullname: Feldmann, H – volume: 26 start-page: 1266 year: 2020 end-page: 1273 ident: B57 article-title: Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States publication-title: Emerg Infect Dis doi: 10.3201/eid2606.200516 contributor: fullname: Thornburg, NJ – volume: 6 year: 2011 ident: B43 article-title: USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response publication-title: PLoS One doi: 10.1371/journal.pone.0022200 contributor: fullname: Uze, G – volume: 349 start-page: 739 year: 2015 end-page: 742 ident: B21 article-title: Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain publication-title: Science doi: 10.1126/science.aab3920 contributor: fullname: Feldmann, H – volume: 173 start-page: 6357 year: 2004 end-page: 6365 ident: B40 article-title: Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis publication-title: J Immunol doi: 10.4049/jimmunol.173.10.6357 contributor: fullname: Xing, Z – volume: 90 start-page: 107233 year: 2021 ident: B42 article-title: Neutrophils and COVID-19: the road so far publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.107233 contributor: fullname: Rodrigues-Mascarenhas, S – volume: 5 start-page: 562 year: 2020 end-page: 569 ident: B10 article-title: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses publication-title: Nat Microbiol doi: 10.1038/s41564-020-0688-y contributor: fullname: Munster, V – volume: 4 year: 2009 ident: B25 article-title: Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses publication-title: PLoS One doi: 10.1371/journal.pone.0005547 contributor: fullname: Jones, SM – volume: 8 start-page: 13319 year: 2018 ident: B48 article-title: Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd publication-title: Sci Rep doi: 10.1038/s41598-018-31510-6 contributor: fullname: Spurkland, A – volume: 60 start-page: 389 year: 2010 end-page: 395 ident: B59 article-title: Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomolgus macaques (Macaca fascicularis) publication-title: Comp Med contributor: fullname: Parnell, MJ – ident: B33 article-title: Merck . 25 January 2021 . Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates; continues development of two investigational therapeutic candidates . Merck , Kenilworth, NJ . https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/ . – volume: 177 start-page: 4851 year: 2020 end-page: 4865 ident: B39 article-title: Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology publication-title: Br J Pharmacol doi: 10.1111/bph.15143 contributor: fullname: Page, CP – volume: 173 start-page: 268 year: 2020 end-page: 277 ident: B5 article-title: Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study publication-title: Ann Intern Med doi: 10.7326/M20-2003 contributor: fullname: Kluge, S – volume: 12 start-page: 180 year: 2012 end-page: 190 ident: B47 article-title: The role of interleukin-2 during homeostasis and activation of the immune system publication-title: Nat Rev Immunol doi: 10.1038/nri3156 contributor: fullname: Sprent, J – volume: 585 start-page: 268 year: 2020 end-page: 272 ident: B29 article-title: Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2324-7 contributor: fullname: de Wit, E – volume: 5 start-page: 667 year: 2020 end-page: 678 ident: B4 article-title: Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(20)30126-6 contributor: fullname: Chen, MH – volume: 2 start-page: 100230 year: 2021 ident: B37 article-title: A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2021.100230 contributor: fullname: Diamond, MS – volume: 103 start-page: 10735 year: 2006 end-page: 10740 ident: B45 article-title: HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0600397103 contributor: fullname: Chin, KC – volume: 28 start-page: 465 year: 2020 end-page: 474.e4 ident: B51 article-title: Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.07.018 contributor: fullname: Diamond, MS – ident: B55 article-title: National Agricultural Library, USDA . 2015 . Chapter 54—Transportation, sale, and handling of certain animals . 7 US Code. https://www.govinfo.gov/content/pkg/USCODE-2015-title7/html/USCODE-2015-title7-chap54.htm . – volume: 579 start-page: 270 year: 2020 end-page: 273 ident: B1 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 contributor: fullname: Shi, ZL – volume: 110 start-page: 1893 year: 2013 end-page: 1898 ident: B30 article-title: Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1209591110 contributor: fullname: Messaoudi, I – volume: 382 start-page: 1199 year: 2020 end-page: 1207 ident: B9 article-title: Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia publication-title: N Engl J Med doi: 10.1056/NEJMoa2001316 contributor: fullname: Feng, Z – volume: 586 start-page: 583 year: 2020 end-page: 588 ident: B15 article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-2607-z contributor: fullname: Cabus, M – ident: B56 article-title: The Royal Society . 2006. The Weatherall report on the use of non-human primates in research. The Royal Society , London, United Kingdom . https://royalsociety.org/policy/publications/2006/weatherall-report/ . – ident: B32 article-title: Weiland N , Sanger DE . 27 July 2020 . Trump administration selects five coronavirus vaccine candidates as finalists . New York Times https://www.nytimes.com/2020/06/03/us/politics/coronavirus-vaccine-trump-moderna.html . – volume: 6 start-page: 148 year: 2006 end-page: 158 ident: B41 article-title: Mucosal vaccines: the promise and the challenge publication-title: Nat Rev Immunol doi: 10.1038/nri1777 contributor: fullname: Kozlowski, PA – volume: 28 start-page: 475 year: 2020 end-page: 485.e5 ident: B27 article-title: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.06.021 contributor: fullname: Whelan, SPJ – volume: 317 start-page: 230 year: 2004 end-page: 234 ident: B44 article-title: TIFAB inhibits TIFA, TRAF-interacting protein with a forkhead-associated domain publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.03.030 contributor: fullname: Inoue, J – volume: 382 start-page: 1708 year: 2020 end-page: 1720 ident: B2 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 contributor: fullname: Zhong, NS – volume: 17 start-page: 388 year: 2016 ident: B60 article-title: systemPipeR: NGS workflow and report generation environment publication-title: BMC Bioinformatics doi: 10.1186/s12859-016-1241-0 contributor: fullname: Girke, T – volume: 389 start-page: 505 year: 2017 end-page: 518 ident: B24 article-title: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32621-6 contributor: fullname: Kieny, MP – volume: 586 start-page: 578 year: 2020 end-page: 582 ident: B13 article-title: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-2608-y contributor: fullname: Munster, VJ – volume: 5 start-page: 4 year: 2020 ident: B22 article-title: A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades publication-title: NPJ Vaccines doi: 10.1038/s41541-019-0155-z contributor: fullname: Marzi, A – ident: B54 article-title: National Research Council . 2011 . Guide for the care and use of laboratory animals , 8th ed . The National Academies Press , Washington, DC . https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf . – volume: 183 start-page: 169 year: 2020 end-page: 184.e13 ident: B12 article-title: A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2 publication-title: Cell doi: 10.1016/j.cell.2020.08.026 contributor: fullname: Diamond, MS – volume: 383 start-page: 1544 year: 2020 end-page: 1555 ident: B16 article-title: Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: N Engl J Med doi: 10.1056/NEJMoa2024671 contributor: fullname: Widge, A – volume: 49 start-page: 223 year: 2019 end-page: 231 ident: B52 article-title: Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.09.055 contributor: fullname: Feldmann, H – volume: 8 start-page: 1372 year: 2017 ident: B31 article-title: Transcriptome analysis of circulating immune cell subsets highlight the role of monocytes in Zaire Ebola virus Makona pathogenesis publication-title: Front Immunol doi: 10.3389/fimmu.2017.01372 contributor: fullname: Messaoudi, I – volume: S1 start-page: 2157-2526-S1-004 year: 2011 ident: B17 article-title: Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections publication-title: J Bioterror Biodef doi: 10.4172/2157-2526.S1-004 contributor: fullname: Falzarano, D – volume: 7 year: 2021 ident: B35 article-title: Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques publication-title: Sci Adv doi: 10.1126/sciadv.abj3627 contributor: fullname: de Wit, E – volume: 586 start-page: 509 year: 2020 end-page: 515 ident: B38 article-title: Animal models for COVID-19 publication-title: Nature doi: 10.1038/s41586-020-2787-6 contributor: fullname: Tseng, CT – volume: 324 start-page: 294 year: 2020 end-page: 296 ident: B3 article-title: Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City publication-title: JAMA doi: 10.1001/jama.2020.10374 contributor: fullname: Milner, JD – volume: 579 start-page: 265 year: 2020 end-page: 269 ident: B7 article-title: A new coronavirus associated with human respiratory disease in China publication-title: Nature doi: 10.1038/s41586-020-2008-3 contributor: fullname: Zhang, YZ – volume: 382 start-page: 929 year: 2020 end-page: 936 ident: B8 article-title: First case of 2019 novel coronavirus in the United States publication-title: N Engl J Med doi: 10.1056/NEJMoa2001191 contributor: fullname: Pillai, SK – volume: 15 start-page: 2269 year: 2019 end-page: 2285 ident: B20 article-title: Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2019.1649532 contributor: fullname: Addo, MM – volume: 21 start-page: 1336 year: 2020 end-page: 1345 ident: B46 article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 publication-title: Nat Immunol doi: 10.1038/s41590-020-0782-6 contributor: fullname: Goulder, P – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: B6 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 contributor: fullname: Cao, B – volume: 584 start-page: 115 year: 2020 end-page: 119 ident: B11 article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Nature doi: 10.1038/s41586-020-2380-z contributor: fullname: Zhang, L – ident: e_1_3_2_9_2 doi: 10.1056/NEJMoa2001191 – ident: e_1_3_2_17_2 doi: 10.1056/NEJMoa2024671 – ident: e_1_3_2_27_2 doi: 10.1101/2021.09.03.458735 – ident: e_1_3_2_57_2 – ident: e_1_3_2_41_2 doi: 10.4049/jimmunol.173.10.6357 – ident: e_1_3_2_44_2 doi: 10.1371/journal.pone.0022200 – ident: e_1_3_2_47_2 doi: 10.1038/s41590-020-0782-6 – ident: e_1_3_2_8_2 doi: 10.1038/s41586-020-2008-3 – ident: e_1_3_2_37_2 doi: 10.1128/mBio.01503-21 – ident: e_1_3_2_45_2 doi: 10.1016/j.bbrc.2004.03.030 – ident: e_1_3_2_59_2 doi: 10.1093/infdis/jir379 – ident: e_1_3_2_19_2 doi: 10.3201/eid2506.181620 – ident: e_1_3_2_40_2 doi: 10.1111/bph.15143 – ident: e_1_3_2_34_2 – ident: e_1_3_2_36_2 doi: 10.1126/sciadv.abj3627 – ident: e_1_3_2_21_2 doi: 10.1080/21645515.2019.1649532 – ident: e_1_3_2_26_2 doi: 10.1371/journal.pone.0005547 – ident: e_1_3_2_56_2 – ident: e_1_3_2_43_2 doi: 10.1016/j.intimp.2020.107233 – ident: e_1_3_2_4_2 doi: 10.1001/jama.2020.10374 – ident: e_1_3_2_3_2 doi: 10.1056/NEJMoa2002032 – ident: e_1_3_2_16_2 doi: 10.1038/s41586-020-2607-z – ident: e_1_3_2_48_2 doi: 10.1038/nri3156 – ident: e_1_3_2_49_2 doi: 10.1038/s41598-018-31510-6 – ident: e_1_3_2_20_2 doi: 10.1371/journal.pntd.0003736 – ident: e_1_3_2_42_2 doi: 10.1038/nri1777 – ident: e_1_3_2_12_2 doi: 10.1038/s41586-020-2380-z – ident: e_1_3_2_33_2 – ident: e_1_3_2_55_2 – ident: e_1_3_2_52_2 doi: 10.1016/j.chom.2020.07.018 – ident: e_1_3_2_30_2 doi: 10.1038/s41586-020-2324-7 – ident: e_1_3_2_32_2 doi: 10.3389/fimmu.2017.01372 – ident: e_1_3_2_61_2 doi: 10.1186/s12859-016-1241-0 – ident: e_1_3_2_2_2 doi: 10.1038/s41586-020-2012-7 – ident: e_1_3_2_5_2 doi: 10.1016/S2468-1253(20)30126-6 – ident: e_1_3_2_39_2 doi: 10.1038/s41586-020-2787-6 – volume: 60 start-page: 389 year: 2010 ident: e_1_3_2_60_2 article-title: Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomolgus macaques (Macaca fascicularis) publication-title: Comp Med contributor: fullname: Brining DL – ident: e_1_3_2_22_2 doi: 10.1126/science.aab3920 – ident: e_1_3_2_51_2 doi: 10.1080/22221751.2020.1747363 – ident: e_1_3_2_6_2 doi: 10.7326/M20-2003 – ident: e_1_3_2_14_2 doi: 10.1038/s41586-020-2608-y – ident: e_1_3_2_13_2 doi: 10.1016/j.cell.2020.08.026 – ident: e_1_3_2_50_2 doi: 10.4049/jimmunol.1800659 – ident: e_1_3_2_46_2 doi: 10.1073/pnas.0600397103 – ident: e_1_3_2_31_2 doi: 10.1073/pnas.1209591110 – ident: e_1_3_2_23_2 doi: 10.1038/s41541-019-0155-z – ident: e_1_3_2_29_2 doi: 10.1038/s41598-018-29401-x – ident: e_1_3_2_54_2 doi: 10.1016/S1473-3099(18)30165-8 – ident: e_1_3_2_10_2 doi: 10.1056/NEJMoa2001316 – ident: e_1_3_2_11_2 doi: 10.1038/s41564-020-0688-y – ident: e_1_3_2_35_2 doi: 10.1038/s41577-018-0005-7 – ident: e_1_3_2_53_2 doi: 10.1016/j.ebiom.2019.09.055 – ident: e_1_3_2_25_2 doi: 10.1016/S0140-6736(16)32621-6 – ident: e_1_3_2_28_2 doi: 10.1016/j.chom.2020.06.021 – ident: e_1_3_2_15_2 doi: 10.1126/science.abc6284 – ident: e_1_3_2_38_2 doi: 10.1016/j.xcrm.2021.100230 – ident: e_1_3_2_18_2 doi: 10.4172/2157-2526.S1-004 – ident: e_1_3_2_7_2 doi: 10.1016/S0140-6736(20)30566-3 – ident: e_1_3_2_58_2 doi: 10.3201/eid2606.200516 – ident: e_1_3_2_24_2 doi: 10.1128/JVI.00794-11 |
SSID | ssj0000331830 |
Score | 2.4472697 |
Snippet | The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited... The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines... ABSTRACT The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With... |
SourceID | doaj pubmedcentral proquest crossref asm2 pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e0337921 |
SubjectTerms | Animals Antibodies, Viral - genetics Antibodies, Viral - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - therapeutic use Ebola Vaccines - genetics Ebola Vaccines - immunology Ebola Vaccines - therapeutic use Ebolavirus - genetics Ebolavirus - immunology Hemorrhagic Fever, Ebola - genetics Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control i.m i.n Macaca mulatta - immunology Research Article rhesus macaques SARS-CoV-2 Vaccination - methods Vaccines Vesicular Stomatitis - genetics Vesicular Stomatitis - immunology Vesicular Stomatitis - prevention & control vesicular stomatitis virus Vesiculovirus - genetics VSV |
SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3LbtQw0KpaIXFBvFleMgJxS0ni93HbUrUgWkTZVW-WX1Ej7SZVkxz6P3wo4zxWbAUSN2s8thPPjGfG9owR-uAsTR0vbMJ8GhJKvU0kL8Dn4UIIF7iyNAYKfzvjJwv65ZJd7qB8ioUZZ7DZN826P8jfSHYuP61tWe-nhAiVxNjxPeAfCg7X3ny-OP-62VkBBODTdEqoebcdrL3Qd76lh_p0_X-zMe9elfxD9xw_RA9GoxHPByo_QjuheozuDc9I3j5Bv36Y69Lj70PKBZhoHING8OH58vQoyRQuK3xWV_1rfIBUrqN5iZfGubKCosencdB1N1xJXd1i27XQoB3glWnMCoBxwxYbfAGqbhXwUd0EXBcAWIam7Bvii7buzd8SOi9vuiY5AA3px4HCU7Q4_vzz8CQZX19ITIyWTQg3imTOiyCD4C5uOuYkBJfyaLYV0kvGnUuNg4IDP4s7z8AWMQzWAMmACs_QblVX4QXCnntmrJOGWUWVTZVLmeWeUJ-ZjHM2Q-8jSfREfN17JrnUkXC6J5zOsxn6OFFMXw-pOP6FeBDpuUGKGbR7APCTHgVS24wy4jnl3ApaEA7_am3mnCNcpiE1M_Ru4gYNEhePUUwV6q7R4HNKBX6oUDP0fOCOzVDxmDYnBGrEFt9sfct2TVVe9Vm9paCKZtnL_5qLV-h-HuMwYmx9_hrttjddeAPWUWvfjuLwG99EDd4 priority: 102 providerName: American Society for Microbiology – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQSkhcEG-Wl4xA3EKT-H2kLVWLREGUrnqz_IqItJtUTXLo_-GHMrZ3q10E4sItGtux5Rl7vrE9Mwi9dZaWjje2YL4MBaXeFpI3YPNwIYQLXFkaHYU_n_Ljc_rpgl1spfqKb8JyeOA8cXu2oox4Tjm3gjaEK1JZWznnCJdlKDM0KustYyrtwSTKarkJqlnLvZVt-_dAFqqIcUFnZljVO7oohez_E878_bnklv45uofuroEj_pAHfB_dCt0DdDunkrx-iH5-M5etx19z2AWYbBwdR_DBl8XJYVEp3Hb4tO9SRj6o1K4ixMQL41zbwafHJ7HT1ZSfpS6vsZ1GaDBmemcGswRiPLTFBp-BulsGfNgPAfcNEBZhaFNDfDb2CQK38PP2ahqKfdCSft1ReITOjz5-Pzgu1hkYChM9ZgvCDcy38yLIILiLB481CcGVPEK3RnrJuHOlcfDhwNbizjPAI4bBPiAZcOExmnV9F54i7LlnxjppmFVU2VK5klnuCfWVqThnc_QmskSvl9Cgk3VSSx0ZpxPjdF3N0bsNx_RlDsfxt4r7kZ83lWIU7UQA2dJr2dL_kq05er2RBg2rLl6lmC7006DB7pQKbFGh5uhJlo6bruJVbU0IlIgdudkZy25J1_5Ikb2loIpW1bP_Mfjn6E4dXTWi-339As3Gqym8BAA12ldprfwCH90Zjw priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELbQIlAviHdDARmBuKUk8SP2ASG2peoibYsou-ot8isQaTdpN4nE_h9-KOMkW9iqvVkTP5LM2PON7ZlB6J3RNDI81yGzkQsptToUPAebh6dpahyXmnpH4ekJP57Rr-fs_F9IoeEH1jeadj6f1Gy12P99uf4EE_5j7wAjPkzHk9P9iJBUht6l_G4CStHf7poOSL9blIkX3mgTZfN6qx1035-wJcQnDR-pepls6akunP9NGPT6Vcr_dNPRQ_RgAJX4cy8Fj9AdVz5G9_o0k-sn6M93dVFY_K0PyQCMwN6pBB-czieHYSxxUeKTquyy9UGlYunhJ54rY4oSihZP_KDLtr-yulhj3TbQoOnpparVAoh-QxcrfAaqcOHwYVU7XOVAmLu66Bris6bq4HEBnRertg7HoEHtMJB7imZHX34cHIdDdoZQeW_akHAlSWxs6oRLufGbkglxzkTcw7pcWMG4MZEyUDBgh3FjGWAVxWCNEAwY8gyNyqp0uwhbbpnSRiimJZU6kiZimltCbaxizlmA3nqWZBvpyDrLJRHZUhdV1vEwS-IAvd9wLLvoQ3XcVnHs-XlVyUfY7gjV6mc2TNhMx5QRyynnOqU54fCtWsfGGMJF5CIVoDcbachgRvpjFlW6qq0zsEmFBDs1lQF63kvH1VAbIQtQuiU3W--y_aQsfnVRv0VKJY3jF7f2uYd2Eu-b4f3tk5do1Kxa9woQU6Nfd3PhL9ylEwM priority: 102 providerName: Scholars Portal |
Title | Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35012339 https://journals.asm.org/doi/10.1128/mbio.03379-21 https://search.proquest.com/docview/2618914479 https://pubmed.ncbi.nlm.nih.gov/PMC8749411 https://doaj.org/article/b1453d6466b74f36931bb1ccc3680e0a |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0NqKkHhBfNMNKiMQb2nzYTvOY9cxNlC3idGqb5G_CpGapGqSh_0ffihnJ5lWBC-8WNbFjp3c2Xdn3wdCH5QkvmJr6VHtG48QLT3O1qDzsDiOlWGJJNZReH7Jzhfky4quDhDtfWGc0b6S2bjY5OMi--lsK7e5mvR2YpPr-YzHJCFBMDlEh8B-76nobvuNLJn6fTzNkE9ymZVjAMeJF9rMMPYuLYxsevCBqPJwjyO5wP1_kzb_NJq8x4XOnqDHnfiIp-00n6IDUzxDD9uEkrfP0a9vYptpfN0GX4Bfjq37CJ5dLS9OvSDBWYEvy8Ll5YNGWW4FTbwUSmUFVDW-sIPmTWucurnFsqmhQ93CC1GJDQDt0S0W-AaY3sbg07IyuFwDYGmqzHXEN3XpBOEMXp7tmso7AV6pu4HMC7Q4-_R9du51eRg8Yf1mvYiJJAqUjg03MVP2-DGMjFE-swLcmmtOmVK-UFBRoHExpSlIJYLCbsApIOQlGhRlYV4jrJmmQiouqExIIv1E-VQyHREdiIAxOkTvLUrSbiFVqdNRQp5aHKYOh2kYDNHHHmPptg3K8a-GJxafd41sLG0HKHc_0o6iUhkQGmlGGJMxWUcMvlXKQCkVMe4bXwzRu54aUlh79kJFFKZsqhS0T56ARhonQ_SqpY67oXoiG6J4j2725rL_BMjdxffuyPvov3seo0eh9dKwnvfhGzSod415C7JTLUfowXS6uPo6cmcPUH5eBVDOCR-5VfQba3wevQ |
link.rule.ids | 230,314,727,780,784,864,885,2102,24318,27924,27925,53147,53160,53173,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3LbtswTChaDNtl6J7NuoeGDbu5s62nj2m7IlnbdFiboDdBL2MeEruo40P_Zx86ynaCpdiA3QxKMm2RFElJJBH6aA2NLc9NxFzsI0qdiSTPwefhQgjreWZoCBQ-n_DRlH69ZtdbiK9iYX6Gurzz-kDXi_YcPwh22Iju6xHKzwtTVAcxISKLQvz4DvCQAP7eGQ6nF6fr3RXoALwar5Jq3h8H6y8gSDd0UZuy_2925v3rkn_on5Nd9Lg3HPGwo_QTtOXLp-hBV0ry7hn69V3fFA5_69IuwGTjEDiCjy5m4-MoyXBR4klVthX5oFOxCCYmnmlrixIeHR4HpIumu5Y6v8OmWcKAZQcvda3nAAybtljjS1B3c4-Pq9rjKgfAzNdFOxBfLqvWBC7g5cVtU0eHoCVdj8g_R9OTL1dHo6ivwBDpEDEbEa4zklgnvPSC27DxmBLvbcyD6ZZLJxm3NtYWHiz4Wtw6BvaIZrAOSAZUeIG2y6r0ewg77pg2VmpmMpqZOLMxM9wR6hKdcM4G6EMgiepFqFatd5JKFQinWsKpNBmgTyuKqZsuHce_Oh4Geq47hSzaLQCYSvVCqUxCGXGccm4EzQmHfzUmsdYSLmMf6wF6v-IGBVIXjlJ06aumVuB3ygx8UZEN0MuOO9aowlFtSgi0iA2-2fiWzZay-NFm9paCZjRJXv3XXLxDD0dX52fqbDw53UeP0hCXEWLt09doe3nb-DdgLS3N2140fgOz5BI4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0Jo6gXhBfFM-jUC8ZTjxR5zHbqVaGXQTo9XeLH9FRGqTamke9n_4oZyTtKITSLxZ57Od-O7sO9t3h9AHaxixIjcRd8RHjDkTSZGDzSPSNLVeZIYFR-FvM3E6Z1-u-NUBEltfmH4G6yNdr9qL_CDZa5f3-Qjlp5UpqiNCaZpFwX_8EHhIkAE6HI3m52e70xVAAF4l26Cat9vB-gv9J3t7URuy_2965u3nkn_sP5MH6H6vOOJRR-mH6MCXj9CdLpXkzWP067teFw5fdGEXYLJxcBzBJ-eL6TiKM1yUeFaVbUY-QCpWQcXEC21tUULR4WkYdNV0z1KXN9g0G2iw6eClrvUSgOHQFmt8Cdvd0uNxVXtc5QBY-LpoG-LLTdWqwAV0Xlw3dXQMu6TrB_JP0Hzy-cfJadRnYIh08JiNqNAZja1LvfSpsOHgMaHeWyKC6pZLJ7mwlmgLBQu2lrCOgz6iOawDkgMVnqJBWZX-OcJOOK6NlZqbjGWGZJZwIxxlLtaxEHyI3geSqC0DqNY6SaQKhFMt4VQSD9HHLcXUugvH8S_E40DPHVKIot0CgKdUL5TKxIxTJ5gQJmU5FfCvxsTWWiok8UQP0bstNyiQunCVoktfNbUCu1NmYIum2RA967hjN1S4qk0ohZp0j2_2vmW_pix-tpG9ZcoyFscv_msu3qK7F-OJ-jqdnb1E95LglhFc7ZNXaLC5bvxrUJY25k0vGb8BhDER1A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rapid+Protection+from+COVID-19+in+Nonhuman+Primates+Vaccinated+Intramuscularly+but+Not+Intranasally+with+a+Single+Dose+of+a+Vesicular+Stomatitis+Virus-Based+Vaccine&rft.jtitle=mBio&rft.au=Furuyama%2C+Wakako&rft.au=Shifflett%2C+Kyle&rft.au=Pinski%2C+Amanda+N&rft.au=Griffin%2C+Amanda+J&rft.date=2022-02-22&rft.eissn=2150-7511&rft.volume=13&rft.issue=1&rft.spage=e0337921&rft_id=info:doi/10.1128%2FMBIO.03379-21&rft_id=info%3Apmid%2F35012339&rft.externalDocID=35012339 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2150-7511&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2150-7511&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2150-7511&client=summon |